{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T09:11:25Z","timestamp":1765357885784,"version":"3.45.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    To give further insights into the safety of SARS-CoV-2 vaccinations in patients with inflammatory rheumatic diseases (IRDs) compared to healthy individuals and to highlight changes over the course of repeated vaccinations.\u00a0In this single-centre study, SARS-CoV-2 vaccinated IRD patients were recruited from the hospital of the University of Munich. Healthcare workers served as the control group. Adverse events following each vaccination were assessed using questionnaires. Descriptive statistics and non-parametric tests were used to illustrate the differences between IRD patients and the control group.\u00a0Between January 1, 2021, and Septemper 30, 2022, 235 IRD patients (60.4% female) and 102 healthy individuals (66.7% female) were enrolled in this study. The frequency of patients who experienced adverse events after the first vaccination (140 [59.6%]) was significantly lower compared to the control group (86 [84.3%]) (OR\u2009=\u20090.274 [95% CI: 0.151\u20130.497];\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.0001). The same was true after the second vaccination (patients: 138 [58.7%]; controls: 80 [78.4%]) (OR\u2009=\u20090.391 [0.228\u20130.670];\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001), and after the third vaccination (123 [56.4%]; 70 [69.3%]) (OR\u2009=\u20090.573 [0.348\u20130.946];\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.029). Local side effects occurred with similar frequency in both groups. However, systemic effects occurred significantly less frequently in patients after all vaccinations than in controls (1. vaccination 97 [41.3%] to 61 [59.8%]: OR\u2009=\u20090.472 [0.294\u20130.759],\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.002; 2. vaccination 91 [38.7%] to 60 [58.8%]: OR\u2009=\u20090.442 [0.275\u20130.710],\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001; 3. vaccination: 85 [39.0%] to 52 [51.5%]: OR\u2009=\u20090.602 [0.374\u20130.969],\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.036).\u00a0SARS-CoV-2 vaccines were well tolerated by patients with IRDs. They experienced systemic side effects less frequently in patients than in healthy controls, suggesting a possible association between IRDs\/immunosuppressive therapies and attenuation of vaccination reactions. Further research is needed to determine the cause of these differences.\n                  <\/jats:p>","DOI":"10.1007\/s00296-025-06013-z","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T04:54:36Z","timestamp":1761195276000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Adverse events of SARS-CoV-2 vaccination in patients with inflammatory rheumatic disease during repeated vaccination: An observational cohort study"],"prefix":"10.1007","volume":"45","author":[{"given":"Liam","family":"Huppke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Gebhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lea","family":"Gr\u00fcmme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Lichtnekert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delila","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3391-236X","authenticated-orcid":false,"given":"Fabian T. H.","family":"Ullrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Wolfrum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alla","family":"Skapenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1681-491X","authenticated-orcid":false,"given":"Hendrik","family":"Schulze-Koops","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"issue":"7821","key":"6013_CR1","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","volume":"584","author":"EJ Williamson","year":"2020","unstructured":"Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE et al (2020) Factors associated with COVID-19-related death using opensafely. Nature 584(7821):430\u2013436","journal-title":"Nature"},{"issue":"7","key":"6013_CR2","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.3899\/jrheum.200755","volume":"48","author":"J Bachiller-Corral","year":"2021","unstructured":"Bachiller-Corral J, Boteanu A, Garcia-Villanueva MJ, de la Puente C, Revenga M, Diaz-Miguel MC et al (2021) Risk of severe COVID-19 infection in patients with inflammatory rheumatic diseases. J Rheumatol 48(7):1098\u20131102","journal-title":"J Rheumatol"},{"issue":"27","key":"6013_CR3","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S et al (2020) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383(27):2603\u20132615","journal-title":"N Engl J Med"},{"issue":"19","key":"6013_CR4","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","volume":"385","author":"SJ Thomas","year":"2021","unstructured":"Thomas SJ, Moreira ED Jr., Kitchin N, Absalon J, Gurtman A, Lockhart S et al (2021) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl J Med 385(19):1761\u20131773","journal-title":"N Engl J Med"},{"issue":"25","key":"6013_CR5","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","volume":"383","author":"EJ Anderson","year":"2020","unstructured":"Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M et al (2020) Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 383(25):2427\u20132438","journal-title":"N Engl J Med"},{"issue":"1","key":"6013_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1093\/rheumatology\/keac305","volume":"62","author":"P Sen","year":"2022","unstructured":"Sen P, Ravichandran N, Nune A, Lilleker JB, Agarwal V, Kardes S et al (2022) COVID-19 vaccination-related adverse events among autoimmune disease patients: results from the COVAD study. Rheumatology (Oxford) 62(1):65\u201376","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"6013_CR7","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00296-021-04972-7","volume":"41","author":"LE Bartels","year":"2021","unstructured":"Bartels LE, Ammitzboll C, Andersen JB, Vils SR, Mistegaard CE, Johannsen AD et al (2021) Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis. Rheumatol Int 41(11):1925\u20131931","journal-title":"Rheumatol Int"},{"issue":"7","key":"6013_CR8","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1473-3099(21)00224-3","volume":"21","author":"C Menni","year":"2021","unstructured":"Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P et al (2021) Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID symptom study app in the UK: a prospective observational study. Lancet Infect Dis 21(7):939\u2013949","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"6013_CR9","first-page":"1663","volume":"25","author":"SA Meo","year":"2021","unstructured":"Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC (2021) COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer\/BioNTech and moderna vaccines. Eur Rev Med Pharmacol Sci 25(3):1663\u20131669","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"12","key":"6013_CR10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.40364","volume":"4","author":"AL Beatty","year":"2021","unstructured":"Beatty AL, Peyser ND, Butcher XE, Cocohoba JM, Lin F, Olgin JE et al (2021) Analysis of COVID-19 vaccine type and adverse effects following vaccination. JAMA Netw Open 4(12):e2140364","journal-title":"JAMA Netw Open"},{"issue":"7","key":"6013_CR11","doi-asserted-by":"publisher","first-page":"249","DOI":"10.15585\/mmwr.mm7107e1","volume":"71","author":"AM Hause","year":"2022","unstructured":"Hause AM, Baggs J, Marquez P, Myers TR, Su JR, Blanc PG et al (2022) Safety monitoring of COVID-19 vaccine booster doses among adults - United States, September 22, 2021-February 6, 2022. MMWR Morb Mortal Wkly Rep 71(7):249\u2013254","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"6013_CR12","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/s41591-022-01715-4","volume":"28","author":"PR Wratil","year":"2022","unstructured":"Wratil PR, Stern M, Priller A, Willmann A, Almanzar G, Vogel E et al (2022) Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern. Nat Med 28(3):496\u2013503","journal-title":"Nat Med"},{"issue":"5","key":"6013_CR13","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1056\/NEJMc2119358","volume":"386","author":"I Nemet","year":"2022","unstructured":"Nemet I, Kliker L, Lustig Y, Zuckerman N, Erster O, Cohen C et al (2022) Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection. N Engl J Med 386(5):492\u2013494","journal-title":"N Engl J Med"},{"issue":"5","key":"6013_CR14","doi-asserted-by":"publisher","first-page":"e338","DOI":"10.1016\/S2665-9913(22)00034-0","volume":"4","author":"L Wieske","year":"2022","unstructured":"Wieske L, van Dam KPJ, Steenhuis M, Stalman EW, Kummer LYL, van Kempen ZLE et al (2022) Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study. Lancet Rheumatol 4(5):e338\u2013e50","journal-title":"Lancet Rheumatol"},{"key":"6013_CR15","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s00296-025-05870-y","volume":"45","author":"A Kirik","year":"2025","unstructured":"Kirik A, \u015eahin N, Bayku M, Bodur H, G\u00fcler T, \u00c7evik R et al (2025) Low vaccination rates and awareness status in patients with rheumatoid arthritis: a nationwide cross-sectional survey study. Rheumatol Int 45:116","journal-title":"Rheumatol Int"},{"key":"6013_CR16","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00296-023-05476-2","volume":"44","author":"R Moraliyska","year":"2024","unstructured":"Moraliyska R, Georgiev T, Bogdanova\u2013Petrova S, Shivach T (2024) Adoption rates of recommended vaccines and influencing factors among patients with inflammatory arthritis: a patient survey. Rheumatol Int 44:165\u2013172","journal-title":"Rheumatol Int"},{"key":"6013_CR17","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1007\/s00296-023-05334-1","volume":"43","author":"A Gastelum\u2013Strozzi","year":"2023","unstructured":"Gastelum\u2013Strozzi A, Flores\u2013Alvarado DE, Pascual\u2013Ramos V, \u00c1lvarez\u2013Hern\u00e1ndez E, Pacheco\u2013Tena CF, Guillermo A et al (2023) The COVID\u201319 epidemic curve and vaccine acceptance among patients with rheumatic diseases: an ecological study. Rheumatol Int 43:1253\u20131264","journal-title":"Rheumatol Int"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-025-06013-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-025-06013-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-025-06013-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T05:12:50Z","timestamp":1763615570000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-025-06013-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":17,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["6013"],"URL":"https:\/\/doi.org\/10.1007\/s00296-025-06013-z","relation":{},"ISSN":["1437-160X"],"issn-type":[{"type":"electronic","value":"1437-160X"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"assertion":[{"value":"2 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the ethics committee of the university hospital of the LMU Munich (18 march 2021, protocol number 21\u20130118) and performed in line with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants gave written informed consent to participate in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"254"}}